Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PP69 β-Amyloid Peptide (1-42), Human

PP69
Purchase on Sigma-Aldrich

Overview

Replacement Information

Products

Catalogue NumberPackaging Qty/Pack
PP69-.25MG Glass bottle .25 mg
Description
OverviewWild-type, human Aβ1-42 peptide. This product is supplied in a form that is not neurotoxic prior to a pre-incubation step. The level of toxicity has been shown to correlate to the extent of β sheet structure.
Catalogue NumberPP69
Brand Family Calbiochem®
SynonymsDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
References
ReferencesCitron, M., et al. 1997. Nature Med. 3, 67.
Hardy, J. 1997. Trends in Neurosci. 20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron 13, 45.
Suzuki, N., et al. 1994. Science 264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.
Product Information
FormLyophilized
FormulationSupplied as a chloride salt.
Hill FormulaC₂₀₃H₃₁₂N₅₆O₅₉S
Chemical formulaC₂₀₃H₃₁₂N₅₆O₅₉S
Hygroscopic Hygroscopic
PreservativeNone
RegionSynthetic peptide corresponding to amino acid residues 1 - 42 of the processed human β-amyloid peptide.
Quality LevelMQ100
Applications
Key Applications Substrate Cleavage Assay
Application NotesSubstrate Cleavage Assays (30-100 μg/ml)
Application Comments
Biological Information
ImmunogenHuman
Purity≥95% by HPLC
Physicochemical Information
Peptide SequenceH-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsReconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
PP69-.25MG 07790788059842

Documentation

β-Amyloid Peptide (1-42), Human SDS

Title

Safety Data Sheet (SDS) 

β-Amyloid Peptide (1-42), Human Certificates of Analysis

TitleLot Number
PP69

References

Reference overview
Citron, M., et al. 1997. Nature Med. 3, 67.
Hardy, J. 1997. Trends in Neurosci. 20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron 13, 45.
Suzuki, N., et al. 1994. Science 264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision26-October-2007 JSW
SynonymsDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
ApplicationSubstrate Cleavage Assays (30-100 μg/ml)
DescriptionWild-type, human Aβ1-42 peptide. A number of mutations, identified in the gene encoding the β-amyloid precursor protein (βAPP), have been linked to early-onset Familial Alzheimer’s Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of βAPP, resulting in increased extracellular concentration of β-amyloid peptide Aβ1-42(43) relative to Aβ1-40. Biophysical and biochemical experiments suggest that Aβ1-42(43) may serve as a catalyst for the aggregation and deposition of β-amyloid peptide (Aβ) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Aβ1-42 revealed that the long form of the peptide is increased in presenilin and βAPP mutants, while other studies have used Aβ specific antibodies to prevent the in vitro fibrillar aggregation of Aβ. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of β sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.
Immunogen speciesHuman
FormLyophilized
FormulationSupplied as a chloride salt.
Recommended reaction conditionsDissolve the lyophilized peptide at 1 mg/ml in 50 mM Tris-HCl, pH ≥9.0. Dilute peptide to an appropriate concentration with calcium, magnesium-free PBS and incubate at 37°C for 24-48 h prior to neurotoxicity studies. Suggested neurotoxic concentration is 30-100 µg/ml.
Chemical formulaC₂₀₃H₃₁₂N₅₆O₅₉S
Peptide SequenceH-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
Purity≥95% by HPLC
Solubility50 mM Tris•HCl, pH >9.0 (≤1 mg/ml)
PreservativeNone
Comments
Storage -20°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsReconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.
Toxicity Standard Handling
ReferencesCitron, M., et al. 1997. Nature Med. 3, 67.
Hardy, J. 1997. Trends in Neurosci. 20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron 13, 45.
Suzuki, N., et al. 1994. Science 264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol. 45, 373.